Cytochrome Therapeutics is a clinical-stage biotechnology company dedicated to developing novel therapeutics that restore mitochondrial Complex I function in Parkinson's disease. Founded in 2019 and headquartered in Cambridge, Massachusetts, Cytochrome targets the fundamental bioenergetic defect that underlies dopaminergic neuron degeneration in PD[1].
The company's lead program, CT-101, is a first-in-class small molecule designed to repair and restore Complex I activity, addressing the root cause of mitochondrial dysfunction in Parkinson's disease rather than just treating symptoms.
Mitochondrial Complex I (NADH:ubiquinone oxidoreductase) deficiency is one of the most consistent biochemical findings in Parkinson's disease:
CT-101 is a small molecule designed to:
| Drug | Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| CT-101 | Complex I restorer | Parkinson's Disease | Phase 1b | Active |
| CT-201 | Complex I restorer | Parkinson's Disease | Preclinical | IND-enabling |
| CT-301 | Neuroprotective | PD-related dementia | Discovery | Research |
Phase 1a (2024): Single ascending dose study in healthy volunteers demonstrated safety and tolerability at doses up to 200mg with no serious adverse events[3].
Phase 1b (2025): Multiple ascending dose study in early PD patients (Hoehn & Yahr stages 1-2) is underway, with primary endpoints including:
The Phase 1b trial employs a randomized, double-blind, placebo-controlled design:
In preclinical studies, CT-101 demonstrated:
| Attribute | Details |
|---|---|
| Headquarters | Cambridge, Massachusetts, USA |
| Founded | 2019 |
| CEO | Dr. Sarah Chen |
| Funding | Series B ($45M, 2023) |
| Investors | Atlas Venture, Third Kind Ventures, Mission Bay Capital |
| Company | Drug | Mechanism | Stage |
|---|---|---|---|
| Cytochrome Therapeutics | CT-101 | Complex I restorer | Phase 1 |
| Denali Therapeutics | DNL151 | LRRK2 inhibitor | Phase 2 |
| Vanqua Bio | VQVN | LRRK2 inhibitor | Phase 1 |
| Clene Nanomedicine | CNM-Au8 | Catalytic antioxidant | Phase 2 |